TY  - JOUR
T1  - Effect of favipiravir use on INR, PT, aPTT tests of COVID-19 patients
AU  - Gül, Mehmet Ali
AU  - Kurt, Nezahat
AU  - Çapraz, Mustafa
AU  - Öztürk, Alpaslan
PY  - 2023
DA  - January
DO  - 10.55895/sshs.1213382
JF  - Sabuncuoglu Serefeddin Health Sciences
JO  - SSHS
PB  - Amasya University
WT  - DergiPark
SN  - 2667-6338
SP  - 14
EP  - 20
VL  - 4
IS  - 3
LA  - en
AB  - The 2019 coronavirus disease (COVID-19) has caused millions of cases worldwide. As the pandemic progresses, understanding the effects of this disease remains important. We aimed to examine the hematological effects of the disease. The research was carried out as a retrospective study, 50 patients using favipiravir and 50 patients not using favipiravir who had positive COVID-19 RT-PCR test in nasal and throat swabs were included in the study. INR, PTT, aPTT tests were evaluated on all patients.  Results of patients using favipiravir; INR 1.3±0.2, PT(s) 16.4±3.4, aPTT(s) 40.7±10.1, while the results of patients who did not use favipiravir were INR 1,2±0.2, PT(s) 14.6±2.5, aPTT(s) was found 38.4±7.8. While PT and INR were found to significantly higher in patients using favipiravir (p<0.05), the elevation in aPTT values was not significant. As a consequence, it was obtained that favipiravir prolongs the clotting time. In the light of these results, it is recommended to consider this in anticoagulant therapy used for treatment.
KW  - COVID-19
KW  - favipiravir
KW  - INR
KW  - PT
KW  - aPTT
CR  - Ciaccio, M., & Agnello, L. (2020). Biochemical biomarkers alterations in Coronavirus Disease 2019 
(COVID-19). Diagnosis (Berl), 7(4), 365-372. doi:10.1515/dx-2020-0057
CR  - Connors, J. M., & Levy, J. H. (2020). COVID-19 and its implications for thrombosis and 
anticoagulation. Blood, 135(23), 2033-2040. doi:10.1182/blood.2020006000
CR  - Conway, E. M., Mackman, N., Warren, R. Q., Wolberg, A. S., Mosnier, L. O., Campbell, R. A., . . . 
Morrissey, J. H. (2022). Understanding COVID-19-associated coagulopathy. Nat Rev Immunol, 
22(10), 639-649. doi:10.1038/s41577-022-00762-9
CR  - Mir, S. M., Tahamtan, A., Nikoo, H. R., Arabi, M. S., Moradi, A. W., Ardakanian, S., & Tabarraei, A. 
(2022). Evaluation of biochemical characteristics of 183 COVID-19 patients: A retrospective 
study. Gene Rep, 26, 101448. doi:10.1016/j.genrep.2021.101448
CR  - Thachil, J. (2020). What do monitoring platelet counts in COVID-19 teach us? Journal of 
Thrombosis and Haemostasis, 18(8), 2071-2072. doi:10.1111/jth.14879
CR  - Tuğçe Atcali , S. Y., Cüneyt Çağlayan , Aykut Ulucan , Adem Kara. (2021). Effects of favipiravir on 
hematologic parameters and bone marrow in the rats. J Exp Clin Med, 39(1), 156-159.
CR  - Yaylaci, S., Dheir, H., Senocak, D., Genc, A. B., Kocayigit, H., Cekic, D., . . . Karabay, O. (2020). The 
effects of favipiravir on hematological parameters of covid-19 patients. Rev Assoc Med Bras 
(1992), 66Suppl 2(Suppl 2), 65-70. doi:10.1590/1806-9282.66.S2.65
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., . . . Cao, B. (2020). Clinical course and risk factors for 
mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 
Lancet, 395(10229), 1054-1062. doi:10.1016/S0140-6736(20)30566-3
UR  - https://doi.org/10.55895/sshs.1213382
L1  - https://dergipark.org.tr/en/download/article-file/2807838
ER  -